SCHEMBL5869947

SCHEMBL5869947

BrCc1ccn(Cc2ccccc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 11/20 0.50
CYP19A1 P11511 2/20 0.46
CACNA1G O43497 3/20 0.45
CACNA1I Q9P0X4 3/20 0.45
MPO P05164 1/20 0.44
TPO P07202 1/20 0.44
CYP3A4 P08684 1/20 0.44
ALDH1A1 P00352 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
HDAC3 O15379 4/20 0.43
HDAC4 P56524 4/20 0.43
HDAC2 Q92769 4/20 0.43
HDAC10 Q969S8 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5869934 0.83 HDAC1 (0.55) HDAC1CYP19A1CACNA1GCACNA1IMPO
SCHEMBL10271012 0.81 HDAC1 (0.50) HDAC1CYP19A1CACNA1GCACNA1IMPO
SCHEMBL8223815 0.80 RAB9A (0.51) CYP19A1ALDH1A1NPC1RAB9AKDM4E
SCHEMBL28862067 0.77 HDAC1 (0.50) HDAC1CYP19A1CACNA1GCACNA1IMPO
SCHEMBL18577540 0.77 CYP19A1 (0.48) HDAC1CYP19A1CACNA1GCACNA1ICYP3A4
SCHEMBL28862061 0.74 HDAC1 (0.44) HDAC1CYP19A1CACNA1GCACNA1IMPO
SCHEMBL8011610 0.73 CACNA1G (0.51) HDAC1CYP19A1CACNA1GCACNA1IALDH1A1
SCHEMBL22149669 0.73 CYP19A1 (0.48) HDAC1CYP19A1CACNA1GCACNA1ICYP3A4
SCHEMBL10247346 0.73 GFER (0.60) HDAC1CYP19A1CACNA1GCACNA1IALDH1A1
SCHEMBL18577609 0.73 CYP19A1 (0.48) HDAC1CYP19A1CACNA1GCACNA1ICYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7045532-B2 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-16 US disclosed
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 US disclosed
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 US disclosed
WO-2002039997-A2 ACE-2 MODULATING COMPOUNDS AND USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof ACE, ACE2, AGTR2 HDAC1 236/4885CYP19A1 876/4885CACNA1G 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.